results
Last reviewed 01/2018
Over 4 years of the trial:
- active treatment reduced:
- systolic blood pressure by 9 mmHg
- diastolic blood pressure by 4 mmHg
- recurrent stroke rates were:
- 10% in the active group
- 14% in the placebo group
- relative risk reduction of 28%
- p<0.0001
- patients receiving single therapy had no significant risk reduction
- patients receiving double therapy had a 43% risk reduction